УДК 542.06 УДК 615.375

DEVELOPMENT OF A METHOD FOR THE SYNTHESIS OF CPG-OLIGONUCLEOTIDES PROMISING FOR IMMUNOTHERAPY OF CANCER Development of a method for the synthesis of CpG-oligonucleotides promising for immunotherapy of cancer

Опубликовано в От химии к технологии шаг за шагом · Том 1, Номер 1 · Страницы 168–172 · Рубрика: Научные статьи
DOI: https://doi.org/10.52957/27821900_2020_01_168
Получено: 16.09.2020 Одобрено: 20.10.2020 Опубликовано: 31.12.2020 Язык публикаций: ENG
This article describes a new method for the synthesis of 2`-O-methoxymethyl monomers applicable for the efficient automated synthesis of 2`-O-modified oligoribonucleotides used for immunotherapy of oncological diseases localized in the gastrointestinal tract.
CpG oligonucleotides, oligoribonucleotides, immunotherapy, oncology
Текст Список литературы
Текст (PDF)
Читать Скачать

1. Berglof A., Turunen J.J., Gissberg O., Bestas B., Blomberg K.E., Smith C.I. Agammaglobulinemia: causative mutations and their implications for novel therapies. Expert Rev. Clin. Immunol. 2013. Vol. 9 (12). P. 1205-1221. DOI:https://doi.org/10.1586/1744666X.2013.850030.

2. Yue X., Q. J. He Chen. Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies. Cancer Cell Int. 2020. Vol. 20:524. DOI:https://doi.org/10.1186/s12935-020-01614-z.

3. Ben-Ali M., Kechout N., Mekki N., et al. Barbouche Genetic Approaches for Definitive Diagnosis of Agammaglobulinemia in Consanguineous Families. J. Clin. Immunol. 2020. Vol. 40(1). P. 96-104. DOI:https://doi.org/10.1007/s10875-019-00706-4. 6.

4. Nijman I.J., Montfrans van J.M., Hoogstraat M., et al. Targeted next-generation sequencing: a novel diagnostic tool for primary immunodeficiencies. J. Allergy Clin. Immunol. 2014. Vol. 133(2). P. 529-534. DOI:https://doi.org/10.1016/j.jaci.2013.08.032.

5. Kanegane H., Hoshino A., Okano T., et al. Flow cytometry-based diagnosis of primary immunodeficiency diseases. Allergol. Int. 2018. Vol. 67(1). P. 43-54. DOI:https://doi.org/10.1016/j.alit.2017.06.003.

6. Dengjel J., Kratchmarova I., Blagoev B. Receptor tyrosine kinase signaling: a view from quantitative proteomics. Mol. Biosyst. 2009. Vol. 5. № 10. P. 1112-1121. DOI: https://doi.org/10.1039/B909534A.

7. Mohamed A.J., Yu L., Bäckesjö C.M., Vargas L., Faryal R., Aints A., Christensson B., Berglöf A., Vihinen M., Nore B.F., Smith C.I. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol. Rev. 2009. Vol. 228. №. 1. P. 114-131. DOI: https://doi.org/10.1007/978-3-319-22714-6_5.

8. Herman S.E., Gordon A.L., Hertlein E., et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011. Vol. 117. № 23. P. 6287-6296. DOI:https://doi.org/10.1182/blood-2011-01-328484.

9. Bernard S., Danglade D., Gardano L., et al. Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma. Int. Journal of Cancer. 2015. Vol. 136. № 12. P. 2761-2774. DOI: https://doi.org/10.1007/978-3-319-18257-5_24.

10. Robak T., Robak P. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies. Int. Rev. Immunol. 2013. Vol. 32(4). P. 358-376. DOI:https://doi.org/10.3109/08830185.2013.786711.

Войти или Создать
* Забыли пароль?